Novel Treatment Of Irritable Bowel Syndrome 1
The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of irritable bowel syndrome (IBS).
1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . A method for the treatment of irritable bowel syndrome (IBS) whereby a pharmaceutically and pharmacologically effective amount of a metabotropic glutamate receptor 5 antagonist, or a pharmaceutically acceptable salt or an optical isomer thereof, is administered to a subject in need of such treatment.
9 . The method according to claim 8 , wherein the IBS is diarrhea predominant IBS.
10 . The method according to claim 8 , wherein the IBS is constipation predominant IBS.
11 . The method according to claim 8 , wherein the IBS is alternating bowel movement predominant IBS.
12 . A method according to any one of claims 8 - 11 , wherein the metabotropic glutamate receptor 5 antagonist is 2-methyl-6-(phenylethynyl)-pyridine.
13 . A method according to claim 12 , wherein the metabotropic glutamate receptor 5 agonist is the hydrochloride salt of 2-methyl-6-(phenylethynyl)-pyridine.
14 . A method according to any one of claims 8 - 11 , wherein the metabotropic glutamate receptor 5 antagonist is 3-[3-(5-Fluoro-pyridin-2-yl)-[1,2,4]oxadiazol-5-yl]-5-methoxymethyl-benzonitrile.